Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
JANX
Stock Latest News
Ratings
Maintained Buy on Janux: Confidence in Lead Asset JANX007 and Strategic Expansion of PSMA Prostate Cancer Franchise
1d ago
JANX
Premium
The Fly
Janux Therapeutics says first patient dosed in Phase 1 study of JANX014
2d ago
JANX
Premium
The Fly
Janux Therapeutics downgraded to Neutral from Buy at UBS
3d ago
JANX
Premium
The Fly
Janux Therapeutics price target lowered to $23 from $25 at Evercore ISI
5d ago
JANX
Premium
The Fly
Janux announces development candidate nomination under Bristol Myers collab
17d ago
BMY
JANX
Premium
The Fly
Janux Therapeutics price target lowered to $80 from $100 at Truist
2M ago
JANX
Premium
Ratings
Janux Therapeutics: Strong Cash Runway, Strategic Bristol-Myers Partnership, and 2026 Clinical Catalysts Underpin Buy Rating
2M ago
JANX
Premium
Ratings
Janux: Encouraging Early T Cell Engager Data, Broad Pipeline, and Strong Cash Runway Support Buy Rating
2M ago
JANX
Premium
The Fly
Janux Therapeutics price target lowered to $100 from $150 at Cantor Fitzgerald
2M ago
JANX
Premium
The Fly
Janux Therapeutics price target lowered to $68 from $72 at Guggenheim
2M ago
JANX
Premium
Ratings
Janux Therapeutics: Rebuilding Confidence After JANX007 Setback with 2026 Clinical Catalysts and Validated PSMA x CD3 Platform
2M ago
JANX
Premium
The Fly
Janux Therapeutics reports Q4 EPS (51c), consensus (64c)
2M ago
JANX
Premium
The Fly
Janux Therapeutics doses first patient in JANX011 trial
2M ago
JANX
Premium
The Fly
Janux Therapeutics CMO Zachariah McIver to depart, William Go to succeed
3M ago
JANX
Premium
Company Announcements
Janux Therapeutics Inks Global Oncology Collaboration With BMS
3M ago
8K
JANX
Premium
Ratings
Janux Therapeutics: Bristol Myers Collaboration Validates Tumor-Activated Platform and Enhances Risk–Reward Profile
3M ago
JANX
Premium
The Fly
Janux Therapeutics enters exclusive license agreement with Bristol Myers
3M ago
BMY
JANX
Premium
The Fly
Janux Therapeutics downgraded to Hold from Buy at Clear Street
3M ago
JANX
Premium
The Fly
Janux Therapeutics price target lowered to $30 from $42 at Piper Sandler
3M ago
JANX
Premium
The Fly
Janux Therapeutics price target lowered to $35 from $49 at BofA
3M ago
JANX
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today,12/29/2025, According to Top Analysts
4M ago
SOC
JANX
Premium
Ratings
Maintaining Buy on Janux: Trial Progress and Undervalued Pipeline Create Compelling Risk–Reward
4M ago
JANX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
